The Multiple Roles of Fibroblast Growth Factor in Diabetic Nephropathy

References

• Zhang H, Nie X, Shi X, et al. Regulatory mechanisms of the Wnt/beta-catenin pathway in diabetic cutaneous ulcers. Front Pharmacol. 2018;9:1114. doi:10.3389/fphar.2018.01114
   PubMed Web of Science ®Google Scholar
• Gnudi L, Coward RJM, Long DA. Diabetic nephropathy: perspective on novel molecular mechanisms. Trends Endocrinol Metab. 2016;27(11):820–830. doi:10.1016/j.tem.2016.07.002
   PubMed Web of Science ®Google Scholar
• Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22(Suppl 1):3–15. doi:10.1111/dom.14007
   PubMed Web of Science ®Google Scholar
• Giorda CB, Carna P, Salomone M, et al. Ten-year comparative analysis of incidence, prognosis, and associated factors for dialysis and renal transplantation in type 1 and type 2 diabetes versus non-diabetes. Acta Diabetol. 2018;55(7):733–740. doi:10.1007/s00592-018-1142-y
   PubMed Web of Science ®Google Scholar
• Bhattacharjee N, Barma S, Konwar N, Dewanjee S, Manna P. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: an update. Eur J Pharmacol. 2016;791:8–24. doi:10.1016/j.ejphar.2016.08.022
   PubMed Web of Science ®Google Scholar
• Han Q, Zhu H, Chen X, Liu Z. Non-genetic mechanisms of diabetic nephropathy. Front Med. 2017;11(3):319–332. doi:10.1007/s11684-017-0569-9
   PubMed Web of Science ®Google Scholar
• Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018;71(6):884–895. doi:10.1053/j.ajkd.2017.10.026
   PubMed Web of Science ®Google Scholar
• Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China. N Engl J Med. 2016;375(9):905–906. doi:10.1056/NEJMc1602469
   PubMed Web of Science ®Google Scholar
• Hui Q, Jin Z, Li X, Liu C, Wang X. FGF family: from drug development to clinical application. Int J Mol Sci. 2018;19(7):1875. doi:10.3390/ijms19071875
   PubMed Web of Science ®Google Scholar
• Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246–1253. doi:10.2337/db07-1476
   PubMed Web of Science ®Google Scholar
• Li X, Wu D, Tian Y. Fibroblast growth factor 19 protects the heart from oxidative stress-induced diabetic cardiomyopathy via activation of AMPK/Nrf2/HO-1 pathway. Biochem Biophys Res Commun. 2018;502(1):62–68. doi:10.1016/j.bbrc.2018.05.121
   PubMed Web of Science ®Google Scholar
• Wang N, Xu TY, Zhang X, et al. Improving hyperglycemic effect of FGF-21 is associated with alleviating inflammatory state in diabetes. Int Immunopharmacol. 2018;56:301–309. doi:10.1016/j.intimp.2018.01.048
   PubMed Web of Science ®Google Scholar
• Cho JM, Yang EH, Quan W, Nam EH, Cheon HG. Discovery of a novel fibroblast activation protein (FAP) inhibitor, BR103354, with anti-diabetic and anti-steatotic effects. Sci Rep. 2020;10(1):21280. doi:10.1038/s41598-020-77978-z
   PubMed Web of Science ®Google Scholar
• Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem. 2010;149(2):121–130. doi:10.1093/jb/mvq121
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8(3):235–253.
   PubMed Web of Science ®Google Scholar
• Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol. 2013;5(6):a015958. doi:10.1101/cshperspect.a015958
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215–266.
   PubMed Web of Science ®Google Scholar
• Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 2005;16(2):233–247. doi:10.1016/j.cytogfr.2005.01.007
   PubMed Web of Science ®Google Scholar
• House SL, Branch K, Newman G, Doetschman T, Schultz Jel J. Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade. Am J Physiol Heart Circ Physiol. 2005;289(5):H2167–H2175. doi:10.1152/ajpheart.00392.2005
   PubMed Web of Science ®Google Scholar
• Braun S, Auf Dem Keller U, Steiling H, Werner S, Brockes JP, Martin P. Fibroblast growth factors in epithelial repair and cytoprotection. Philos Trans R Soc Lond B Biol Sci. 2004;359(1445):753–757. doi:10.1098/rstb.2004.1464
   PubMed Web of Science ®Google Scholar
• Gupte VV, Ramasamy SK, Reddy R, et al. Overexpression of fibroblast growth factor-10 during both inflammatory and fibrotic phases attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med. 2009;180(5):424–436. doi:10.1164/rccm.200811-1794OC
   PubMed Web of Science ®Google Scholar
• Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006;281(23):15694–15700. doi:10.1074/jbc.M601252200
   PubMed Web of Science ®Google Scholar
• Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16(2):139–149. doi:10.1016/j.cytogfr.2005.01.001
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–1134. doi:10.1016/j.cell.2010.06.011
   PubMed Web of Science ®Google Scholar
• Schlessinger J, Plotnikov AN, Ibrahimi OA, et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell. 2000;6(3):743–750. doi:10.1016/S1097-2765(00)00073-3
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Signal transduction. Autoinhibition control. Science. 2003;300(5620):750–752. doi:10.1126/science.1082024
   PubMedGoogle Scholar
• Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 2012;26(4):312–324. doi:10.1101/gad.184788.111
   PubMed Web of Science ®Google Scholar
• Smith ER, McMahon LP, Holt SG. Fibroblast growth factor 23. Ann Clin Biochem. 2013;51(2):203–227. doi:10.1177/0004563213510708
   PubMed Web of Science ®Google Scholar
• Degirolamo C, Sabba C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016;15(1):51–69. doi:10.1038/nrd.2015.9
   PubMed Web of Science ®Google Scholar
• Kuro-o M. The Klotho proteins in health and disease. Nat Rev Nephrol. 2019;15(1):27–44. doi:10.1038/s41581-018-0078-3
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–188. doi:10.1152/physrev.00045.2011
   PubMed Web of Science ®Google Scholar
• Magee C, Grieve DJ, Watson CJ, Brazil DP. Diabetic nephropathy: a tangled web to unweave. Cardiovasc Drugs Ther. 2017;31(5–6):579–592. doi:10.1007/s10557-017-6755-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Wen Z, Han L, et al. Research progress on the pathological mechanisms of podocytes in diabetic nephropathy. J Diabetes Res. 2020;2020:7504798. doi:10.1155/2020/7504798
   PubMed Web of Science ®Google Scholar
• Sifuentes-Franco S, Padilla-Tejeda DE, Carrillo-Ibarra S, Miranda-Díaz AG. Oxidative stress, apoptosis, and mitochondrial function in diabetic nephropathy. Int J Endocrinol. 2018;2018:1875870. doi:10.1155/2018/1875870
   PubMed Web of Science ®Google Scholar
• Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol. 2020;16(4):206–222. doi:10.1038/s41581-019-0234-4
   PubMed Web of Science ®Google Scholar
• Chang -T-T, Chen J-W. The role of chemokines and chemokine receptors in diabetic nephropathy. Int J Mol Sci. 2020;21(9):3172. doi:10.3390/ijms21093172
   PubMed Web of Science ®Google Scholar
• Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013;124(3):139–152. doi:10.1042/CS20120198
   PubMed Web of Science ®Google Scholar
• Luis-Rodriguez D, Martinez-Castelao A, Gorriz JL, De-alvaro F, Navarro-Gonzalez JF. Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J Diabetes. 2012;3(1):7–18. doi:10.4239/wjd.v3.i1.7
   PubMedGoogle Scholar
• Rivero A, Mora C, Muros M, Garcia J, Herrera H, Navarro-Gonzalez JF. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci (Lond). 2009;116(6):479–492. doi:10.1042/CS20080394
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7(6):327–340. doi:10.1038/nrneph.2011.51
   PubMed Web of Science ®Google Scholar
• Giacco F, Brownlee M, Schmidt AM. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–1070. doi:10.1161/CIRCRESAHA.110.223545
   PubMed Web of Science ®Google Scholar
• Tavafi M. Diabetic nephropathy and antioxidants. J Nephropathol. 2013;2(1):20–27. doi:10.5812/nephropathol.9093
   PubMedGoogle Scholar
• Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018;14(5):291–312.
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365(9467):1333–1346. doi:10.1016/S0140-6736(05)61032-X
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Chang Y-F, Ferrell RE, Petro N, Ellis DE. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities?: further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int. 2002;62(3):963–970.
   PubMed Web of Science ®Google Scholar
• Dib SA. [Insulin resistance and metabolic syndrome in type 1 diabetes mellitus]. Arq Bras Endocrinol Metabol. 2006;50(2):250–263. Portugese. doi:10.1590/S0004-27302006000200011
   PubMedGoogle Scholar
• Noh H, King GL. The role of protein kinase C activation in diabetic nephropathy. Kidney Int Suppl. 2007;72(106):S49–S53. doi:10.1038/sj.ki.5002386
   Google Scholar
• Chung SS, Ho EC, Lam KS, Chung SK. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol. 2003;14(8 Suppl 3):S233–236. doi:10.1097/01.ASN.0000077408.15865.06
   PubMed Web of Science ®Google Scholar
• Sanajou D, Ghorbani Haghjo A, Argani H, Aslani S. AGE-RAGE axis blockade in diabetic nephropathy: current status and future directions. Eur J Pharmacol. 2018;833:158–164. doi:10.1016/j.ejphar.2018.06.001
   PubMed Web of Science ®Google Scholar
• Kang JS, Lee SJ, Lee JH, et al. Angiotensin II-mediated MYH9 downregulation causes structural and functional podocyte injury in diabetic kidney disease. Sci Rep. 2019;9(1):7679. doi:10.1038/s41598-019-44194-3
   PubMedGoogle Scholar
• Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol. 2011;6:395–423. doi:10.1146/annurev.pathol.4.110807.092150
   PubMed Web of Science ®Google Scholar
• Kato M, Natarajan R. Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. Nat Rev Nephrol. 2019;15(6):327–345. doi:10.1038/s41581-019-0135-6
   PubMed Web of Science ®Google Scholar
• Callaghan MJ, Chang EI, Seiser N, et al. Pulsed electromagnetic fields accelerate normal and diabetic wound healing by increasing endogenous FGF-2 release. Plast Reconstr Surg. 2008;121(1):130–141. doi:10.1097/01.prs.0000293761.27219.84
   PubMed Web of Science ®Google Scholar
• So WY, Leung PS. Fibroblast growth factor 21 as an emerging therapeutic target for type 2 diabetes mellitus. Med Res Rev. 2016;36(4):672–704. doi:10.1002/med.21390
   PubMed Web of Science ®Google Scholar
• Yang H, Feng A, Lin S, et al. Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart. Cell Death Dis. 2018;9(2):1–4.
   PubMedGoogle Scholar
• Donate-Correa J, Martín-Núñez E, Ferri C, et al. FGF23 and klotho levels are independently associated with diabetic foot syndrome in type 2 diabetes mellitus. J Clin Med. 2019;8(4):448. doi:10.3390/jcm8040448
   PubMed Web of Science ®Google Scholar
• Katoh M. Therapeutics targeting FGF signaling network in human diseases. Trends Pharmacol Sci. 2016;37(12):1081–1096. doi:10.1016/j.tips.2016.10.003
   PubMed Web of Science ®Google Scholar
• Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004;20(11):563–569. doi:10.1016/j.tig.2004.08.007
   PubMed Web of Science ®Google Scholar
• Raju R, Palapetta SM, Sandhya VK, et al. A network map of FGF-1/FGFR signaling system. J Signal Transduct. 2014;2014:962962. doi:10.1155/2014/962962
   PubMedGoogle Scholar
• Gasser E, Moutos CP, Downes M, Evans RM. FGF1 - a new weapon to control type 2 diabetes mellitus. Nat Rev Endocrinol. 2017;13(10):599–609. doi:10.1038/nrendo.2017.78
   PubMed Web of Science ®Google Scholar
• Jonker JW, Suh JM, Atkins AR, et al. A PPARγ–FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature. 2012;485(7398):391–394. doi:10.1038/nature10998
   PubMed Web of Science ®Google Scholar
• Suh JM, Jonker JW, Ahmadian M, et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature. 2014;513(7518):436–439. doi:10.1038/nature13540
   PubMed Web of Science ®Google Scholar
• Fan L, Ding L, Lan J, Niu J, He Y, Song L. Fibroblast growth factor-1 improves insulin resistance via repression of JNK-mediated inflammation. Front Pharmacol. 2019;10. doi:10.3389/fphar.2019.01478
   Web of Science ®Google Scholar
• Li Z, Liu J, Wang W, Zhao Y, Yang D, Geng X. Investigation of hub genes involved in diabetic nephropathy using biological informatics methods. Ann Transl Med. 2020;8(17):1087. doi:10.21037/atm-20-5647
   PubMed Web of Science ®Google Scholar
• Giribabu N, Karim K, Kilari EK, Salleh N. Phyllanthus niruri leaves aqueous extract improves kidney functions, ameliorates kidney oxidative stress, inflammation, fibrosis and apoptosis and enhances kidney cell proliferation in adult male rats with diabetes mellitus. J Ethnopharmacol. 2017;205:123–137. doi:10.1016/j.jep.2017.05.002
   PubMed Web of Science ®Google Scholar
• Liang G, Song L, Chen Z, et al. Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism. Kidney Int. 2018;93(1):95–109. doi:10.1016/j.kint.2017.05.013
   PubMed Web of Science ®Google Scholar
• Wang D, Jin M, Zhao X, et al. FGF1(ΔHBS) ameliorates chronic kidney disease via PI3K/AKT mediated suppression of oxidative stress and inflammation. Cell Death Dis. 2019;10(6):464. doi:10.1038/s41419-019-1696-9
   PubMedGoogle Scholar
• Wu Y, Li Y, Jiang T, et al. Reduction of cellular stress is essential for Fibroblast growth factor 1 treatment for diabetic nephropathy. J Cell Mol Med. 2018;22(12):6294–6303. doi:10.1111/jcmm.13921
   PubMed Web of Science ®Google Scholar
• Pena AM, Chen S, Feng B, et al. Prevention of diabetic nephropathy by modified acidic fibroblast growth factor. Nephron. 2017;137(3):221–236. doi:10.1159/000478745
   PubMed Web of Science ®Google Scholar
• Perlman AS, Chevalier JM, Wilkinson P, et al. Serum inflammatory and immune mediators are elevated in early stage diabetic nephropathy. Ann Clin Lab Sci. 2015;45(3):256–263.
   PubMed Web of Science ®Google Scholar
• Stephan CC, Chang KC, LeJeune W, et al. Role for heparin-binding growth factors in glucose-induced vascular dysfunction. Diabetes. 1998;47(11):1771–1778. doi:10.2337/diabetes.47.11.1771
   PubMed Web of Science ®Google Scholar
• Strutz F, Zeisberg M, Hemmerlein B, et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int. 2000;57(4):1521–1538. doi:10.1046/j.1523-1755.2000.00997.x
   PubMed Web of Science ®Google Scholar
• Strutz F, Zeisberg M, Ziyadeh FN, et al. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int. 2002;61(5):1714–1728. doi:10.1046/j.1523-1755.2002.00333.x
   PubMed Web of Science ®Google Scholar
• Vasko R, Koziolek M, Ikehata M, et al. Role of basic fibroblast growth factor (FGF-2) in diabetic nephropathy and mechanisms of its induction by hyperglycemia in human renal fibroblasts. Am J Physiol Renal Physiol. 2009;296(6):F1452–F1463. doi:10.1152/ajprenal.90352.2008
   PubMed Web of Science ®Google Scholar
• Masola V, Gambaro G, Tibaldi E, et al. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem. 2012;287(2):1478–1488. doi:10.1074/jbc.M111.279836
   PubMed Web of Science ®Google Scholar
• Masola V, Zaza G, Onisto M, Lupo A, Gambaro G. Impact of heparanase on renal fibrosis. J Transl Med. 2015;13:181.
   PubMed Web of Science ®Google Scholar
• Masola V, Zaza G, Gambaro G. Sulodexide and glycosaminoglycans in the progression of renal disease. Nephrol Dial Transplant. 2014;29(Suppl 1):i74–i79. doi:10.1093/ndt/gft389
   PubMedGoogle Scholar
• Masola V, Zaza G, Secchi MF, Gambaro G, Lupo A, Onisto M. Heparanase is a key player in renal fibrosis by regulating TGF-β expression and activity. Biochimica et Biophysica Acta. 2014;1843(9):2122–2128. doi:10.1016/j.bbamcr.2014.06.005
   PubMed Web of Science ®Google Scholar
• Floege J, Kriz W, Schulze M, et al. Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest. 1995;96(6):2809–2819. doi:10.1172/JCI118351
   PubMed Web of Science ®Google Scholar
• Villanueva S, Contreras F, Tapia A, et al. Basic fibroblast growth factor reduces functional and structural damage in chronic kidney disease. Am J Physiol Renal Physiol. 2014;306(4):F430–441. doi:10.1152/ajprenal.00720.2012
   PubMed Web of Science ®Google Scholar
• Okamoto K, Honda K, Doi K, et al. Glypican-5 increases susceptibility to nephrotic damage in diabetic kidney. Am J Pathol. 2015;185(7):1889–1898. doi:10.1016/j.ajpath.2015.03.025
   PubMed Web of Science ®Google Scholar
• Floege J, Hudkins KL, Eitner F, et al. Localization of fibroblast growth factor-2 (basic FGF) and FGF receptor-1 in adult human kidney. Kidney Int. 1999;56(3):883–897. doi:10.1046/j.1523-1755.1999.00637.x
   PubMed Web of Science ®Google Scholar
• Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17(5):790–797. doi:10.1016/j.cmet.2013.03.019
   PubMed Web of Science ®Google Scholar
• Nakano T, Shiizaki K, Miura Y, et al. Increased fibroblast growth factor-21 in chronic kidney disease is a trade-off between survival benefit and blood pressure dysregulation. Sci Rep. 2019;9(1):19247. doi:10.1038/s41598-019-55643-4
   PubMedGoogle Scholar
• Looker HC, Colombo M, Hess S, et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney Int. 2015;88(4):888–896. doi:10.1038/ki.2015.199
   PubMed Web of Science ®Google Scholar
• Yu W, Zhu H, Chen X, et al. Genetic variants flanking the FGF21 gene were associated with renal function in Chinese patients with type 2 diabetes. J Diabetes Res. 2019;2019:9387358. doi:10.1155/2019/9387358
   PubMed Web of Science ®Google Scholar
• Lin Z, Zhou Z, Liu Y, et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One. 2011;6(4):e18398. doi:10.1371/journal.pone.0018398
   PubMed Web of Science ®Google Scholar
• Lee CH, Hui EY, Woo YC, et al. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. J Clin Endocrinol Metab. 2015;100(4):1368–1375. doi:10.1210/jc.2014-3465
   PubMed Web of Science ®Google Scholar
• Gamrot Z, Adamczyk P, Świętochowska E, Roszkowska-Bjanid D, Gamrot J, Szczepańska M. Fibroblast growth factor 21 (FGF21) in children and adolescents with chronic kidney disease. Physiol Res. 2020;69(3):451–460. doi:10.33549/physiolres.934307
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Koyama D, Igarashi R, et al. Serum endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease and various metabolic dysfunctions in aged patients. Intern Med. 2020;59(3):345–355. doi:10.2169/internalmedicine.3597-19
   PubMed Web of Science ®Google Scholar
• Jian WX, Peng WH, Jin J, et al. Association between serum fibroblast growth factor 21 and diabetic nephropathy. Metabolism. 2012;61(6):853–859. doi:10.1016/j.metabol.2011.10.012
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Khandan A, Momeni A, et al. Circulating levels of fibroblast growth factor 21 in early-stage diabetic kidney disease. Ir J Med Sci. 2017;186(3):785–794. doi:10.1007/s11845-017-1554-7
   PubMed Web of Science ®Google Scholar
• Zhang C, Shao M, Yang H, et al. Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation. PLoS One. 2013;8(12):e82275. doi:10.1371/journal.pone.0082275
   PubMed Web of Science ®Google Scholar
• Angel GM, Paola VV, Froylan David MS, et al. Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease. Ther Adv Endocrinol Metab. 2021;12:20420188211001160. doi:10.1177/20420188211001160
   Web of Science ®Google Scholar
• Iglesias P, Selgas R, Romero S, Diez JJ. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol. 2012;167(3):301–309. doi:10.1530/EJE-12-0357
   PubMed Web of Science ®Google Scholar
• Kim HW, Lee JE, Cha JJ, et al. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. Endocrinology. 2013;154(9):3366–3376. doi:10.1210/en.2012-2276
   PubMed Web of Science ®Google Scholar
• Kim KH, Jeong YT, Oh H, et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med. 2013;19(1):83–92. doi:10.1038/nm.3014
   PubMed Web of Science ®Google Scholar
• Wei W, An XR, Jin SJ, Li XX, Xu M. Inhibition of insulin resistance by PGE1 via autophagy-dependent FGF21 pathway in diabetic nephropathy. Sci Rep. 2018;8(1):9. doi:10.1038/s41598-017-18427-2
   PubMedGoogle Scholar
• Li S, Guo X, Zhang T, et al. Fibroblast growth factor 21 ameliorates high glucose-induced fibrogenesis in mesangial cells through inhibiting STAT5 signaling pathway. Biomed Pharmacother. 2017;93:695–704. doi:10.1016/j.biopha.2017.06.100
   PubMed Web of Science ®Google Scholar
• Weng W, Ge T, Wang Y, et al. Therapeutic effects of fibroblast growth factor-21 on diabetic nephropathy and the possible mechanism in type 1 diabetes mellitus mice. Diabetes Metab J. 2020;44(4):566–580. doi:10.4093/dmj.2019.0089
   PubMed Web of Science ®Google Scholar
• Liu M-H. FGF-21 alleviates diabetes-associated vascular complications: inhibiting NF-κB/NLRP3 inflammasome-mediated inflammation? Int J Cardiol. 2015;185:320–321. doi:10.1016/j.ijcard.2015.03.165
   PubMed Web of Science ®Google Scholar
• Chen K, Zhang J, Zhang W, et al. ATP-P2X4 signaling mediates NLRP3 inflammasome activation: a novel pathway of diabetic nephropathy. Int J Biochem Cell Biol. 2013;45(5):932–943. doi:10.1016/j.biocel.2013.02.009
   PubMed Web of Science ®Google Scholar
• Lin S, Yu L, Ni Y, et al. Fibroblast growth factor 21 attenuates diabetes-induced renal fibrosis by negatively regulating TGF-beta-p53-Smad2/3-mediated epithelial-to-mesenchymal transition via activation of AKT. Diabetes Metab J. 2020;44(1):158–172. doi:10.4093/dmj.2018.0235
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhang J, Guo W, et al. Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy. Free Radic Biol Med. 2016;93:94–109. doi:10.1016/j.freeradbiomed.2016.02.002
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhang X, Ma F, et al. The role of Akt2 in the protective effect of fenofibrate against diabetic nephropathy. Int J Biol Sci. 2020;16(4):553–567. doi:10.7150/ijbs.40643
   PubMed Web of Science ®Google Scholar
• Xie Y, Su N, Yang J, et al. FGF/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020;5(1):181.
   PubMed Web of Science ®Google Scholar
• Rodelo-Haad C, Santamaria R, Muñoz-Castañeda JR, Pendón-ruiz de Mier MV, Martin-Malo A, Rodriguez M. FGF23, biomarker or target? Toxins. 2019;11(3):175. doi:10.3390/toxins11030175
   PubMed Web of Science ®Google Scholar
• Muñoz-Castañeda JR, Rodelo-Haad C, Pendon-ruiz de Mier MV, Martin-Malo A, Santamaria R, Rodriguez M. Klotho/FGF23 and Wnt signaling as important players in the comorbidities associated with chronic kidney disease. Toxins. 2020;12(3):185. doi:10.3390/toxins12030185
   PubMed Web of Science ®Google Scholar
• Buchanan S, Combet E, Stenvinkel P, Shiels PG. Klotho, aging, and the failing kidney. Front Endocrinol (Lausanne). 2020;11:560. doi:10.3389/fendo.2020.00560
   PubMed Web of Science ®Google Scholar
• Nowak N. Protective factors as biomarkers and targets for prevention and treatment of diabetic nephropathy: from current human evidence to future possibilities. J Diabetes Investig. 2020;11(5):1085–1096. doi:10.1111/jdi.13257
   PubMed Web of Science ®Google Scholar
• Bouma-de Krijger A, Bots ML, Vervloet MG, et al. Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease. Nephrol Dial Transplant. 2014;29(1):88–97. doi:10.1093/ndt/gft456
   PubMed Web of Science ®Google Scholar
• Kuro OM. Klotho and endocrine fibroblast growth factors: markers of chronic kidney disease progression and cardiovascular complications? Nephrol Dial Transplant. 2019;34(1):15–21. doi:10.1093/ndt/gfy126
   PubMed Web of Science ®Google Scholar
• Komaba H, Fukagawa M. The role of FGF23 in CKD–with or without Klotho. Nat Rev Nephrol. 2012;8(8):484–490. doi:10.1038/nrneph.2012.116
   PubMed Web of Science ®Google Scholar
• Wahl P, Xie H, Scialla J, et al. Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. Diabetes Care. 2012;35(5):994–1001. doi:10.2337/dc11-2235
   PubMed Web of Science ®Google Scholar
• Garland JS, Holden RM, Ross R, et al. Insulin resistance is associated with fibroblast growth factor-23 in stage 3–5 chronic kidney disease patients. J Diabetes Complications. 2014;28(1):61–65. doi:10.1016/j.jdiacomp.2013.09.004
   PubMed Web of Science ®Google Scholar
• Agarwal R, Duffin KL, Laska DA, Voelker JR, Breyer MD, Mitchell PG. A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease. Nephrol Dial Transplant. 2014;29(12):2293–2302. doi:10.1093/ndt/gfu255
   PubMed Web of Science ®Google Scholar
• Lu X, Hu MC. Klotho/FGF23 axis in chronic kidney disease and cardiovascular disease. Kidney Dis (Basel). 2017;3(1):15–23. doi:10.1159/000452880
   PubMed Web of Science ®Google Scholar
• David V, Martin A, Isakova T, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89(1):135–146. doi:10.1038/ki.2015.290
   PubMed Web of Science ®Google Scholar
• Francis C, David V. Inflammation regulates fibroblast growth factor 23 production. Curr Opin Nephrol Hypertens. 2016;25(4):325–332. doi:10.1097/MNH.0000000000000232
   PubMed Web of Science ®Google Scholar
• Czaya B, Faul C. FGF23 and inflammation-a vicious coalition in CKD. Kidney Int. 2019;96(4):813–815. doi:10.1016/j.kint.2019.05.018
   PubMed Web of Science ®Google Scholar
• Zhang X, Guo K, Xia F, Zhao X, Huang Z, Niu J. FGF23(C-tail) improves diabetic nephropathy by attenuating renal fibrosis and inflammation. BMC Biotechnol. 2018;18(1):33. doi:10.1186/s12896-018-0449-7
   PubMedGoogle Scholar
• Farias-Basulto A, Martinez-Ramirez HR, Gomez-Garcia EF, et al. Circulating levels of soluble klotho and fibroblast growth factor 23 in diabetic patients and its association with early nephropathy. Arch Med Res. 2018;49(7):451–455. doi:10.1016/j.arcmed.2019.01.008
   PubMed Web of Science ®Google Scholar
• Titan SM, Zatz R, Graciolli FG, et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol. 2011;6(2):241–247. doi:10.2215/CJN.04250510
   PubMed Web of Science ®Google Scholar
• Silswal N, Touchberry CD, Daniel DR, et al. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab. 2014;307(5):E426–E436. doi:10.1152/ajpendo.00264.2014
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Sonmez A, Saglam M, et al. Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. Am J Nephrol. 2014;40(3):208–214. doi:10.1159/000366169
   PubMed Web of Science ®Google Scholar
• Zanchi C, Locatelli M, Benigni A, et al. Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. PLoS One. 2013;8(8):e70775. doi:10.1371/journal.pone.0070775
   PubMed Web of Science ®Google Scholar
• Dokumacioglu E, Iskender H, Musmul A. Effect of hesperidin treatment on α-Klotho/FGF-23 pathway in rats with experimentally-induced diabetes. Biomed Pharmacother. 2019;109:1206–1210. doi:10.1016/j.biopha.2018.10.192
   PubMed Web of Science ®Google Scholar
• Ge X, Xi L, Wang Q, et al. Circular RNA Circ_0000064 promotes the proliferation and fibrosis of mesangial cells via miR-143 in diabetic nephropathy. Gene. 2020;758:144952. doi:10.1016/j.gene.2020.144952
   PubMed Web of Science ®Google Scholar
• Mou X, Chenv JW, Zhou DY, et al. A novel identified circular RNA, circ_0000491, aggravates the extracellular matrix of diabetic nephropathy glomerular mesangial cells through suppressing miR‑101b by targeting TGFβRI. Mol Med Rep. 2020;22(5):3785–3794.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang X, Wang ZY, Li L. Circ_0080425 inhibits cell proliferation and fibrosis in diabetic nephropathy via sponging miR-24-3p and targeting fibroblast growth factor 11. J Cell Physiol. 2020;235(5):4520–4529. doi:10.1002/jcp.29329
   PubMed Web of Science ®Google Scholar
• Md Dom ZI, Satake E, Skupien J, et al. Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes. Sci Transl Med. 2021;13:600. doi:10.1126/scitranslmed.abd2699
   Web of Science ®Google Scholar
• Huh SH, Ha L, Jang HS. Nephron progenitor maintenance is controlled through fibroblast growth factors and sprouty1 interaction. J Am Soc Nephrol. 2020;31(11):2559–2572. doi:10.1681/ASN.2020040401
   PubMed Web of Science ®Google Scholar
• Barak H, Huh SH, Chen S, et al. FGF9 and FGF20 maintain the stemness of nephron progenitors in mice and man. Dev Cell. 2012;22(6):1191–1207. doi:10.1016/j.devcel.2012.04.018
   PubMed Web of Science ®Google Scholar
• Xu W, Yang Z, Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr. 2015;9(4):317–324. doi:10.1080/19336918.2015.1016686
   PubMed Web of Science ®Google Scholar
• Xuejiao S, Lin C, Zhiyi H. PI3K/Akt-Nrf2 and anti-inflammation effect of macrolides in chronic obstructive pulmonary disease. Curr Drug Metab. 2019;20(4):301–304. doi:10.2174/1389200220666190227224748
   PubMed Web of Science ®Google Scholar
• Yang S, Guo Y, Zhang W, Zhang J, Zhang Y, Xu P. Effect of FGF-21 on implant bone defects through hepatocyte growth factor (HGF)-mediated PI3K/AKT signaling pathway. Biomed Pharmacother. 2019;109:1259–1267. doi:10.1016/j.biopha.2018.10.150
   PubMed Web of Science ®Google Scholar
• Tang QY, Wei JX, Xue SF, Liu GH, Fu LX. Fibrogrowth factor-2 protects against acute lung injury by activating the PI3K/Akt signaling pathway. J Biol Regul Homeost Agents. 2020;34(5):1679–1688.
   PubMed Web of Science ®Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655. doi:10.1126/science.296.5573.1655
   PubMed Web of Science ®Google Scholar
• Rizvi F, Shukla S, Kakkar P. Essential role of PH domain and leucine-rich repeat protein phosphatase 2 in Nrf2 suppression via modulation of Akt/GSK3beta/Fyn kinase axis during oxidative hepatocellular toxicity. Cell Death Dis. 2014;5:e1153. doi:10.1038/cddis.2014.118
   PubMed Web of Science ®Google Scholar
• Feng X, Guan W, Zhao Y, et al. Dexmedetomidine ameliorates lipopolysaccharide-induced acute kidney injury in rats by inhibiting inflammation and oxidative stress via the GSK-3beta/Nrf2 signaling pathway. J Cell Physiol. 2019;234(10):18994–19009. doi:10.1002/jcp.28539
   PubMed Web of Science ®Google Scholar
• Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol. 2001;21(3):893. doi:10.1128/MCB.21.3.893-901.2001
   PubMed Web of Science ®Google Scholar
• Tesch GH, Ma FY, Han Y, Liles JT, Breckenridge DG, Nikolic-Paterson DJ. ASK1 inhibitor halts progression of diabetic nephropathy in nos3-deficient mice. Diabetes. 2015;64(11):3903.
   PubMed Web of Science ®Google Scholar
• Amos LA, Ma FY, Tesch GH, et al. ASK1 inhibitor treatment suppresses p38/JNK signalling with reduced kidney inflammation and fibrosis in rat crescentic glomerulonephritis. J Cell Mol Med. 2018;22(9):4522–4533. doi:10.1111/jcmm.13705
   PubMed Web of Science ®Google Scholar
• Lu Q, Wang -W-W, Zhang M-Z, et al. ROS induces epithelial-mesenchymal transition via the TGF-β1/PI3K/Akt/mTOR pathway in diabetic nephropathy. Exp Ther Med. 2019;17(1):835–846.
   PubMed Web of Science ®Google Scholar
• Fantus D, Rogers NM, Grahammer F, Huber TB, Thomson AW. Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat Rev Nephrol. 2016;12(10):587–609.
   PubMed Web of Science ®Google Scholar
• Kawarada Y, Inoue Y, Kawasaki F, et al. TGF-β induces p53/Smads complex formation in the PAI-1 promoter to activate transcription. Sci Rep. 2016;6:35483. doi:10.1038/srep35483
   PubMed Web of Science ®Google Scholar
• Higgins SP, Tang Y, Higgins CE, et al. TGF-β1/p53 signaling in renal fibrogenesis. Cell Signal. 2018;43:1–10. doi:10.1016/j.cellsig.2017.11.005
   PubMed Web of Science ®Google Scholar
• Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor–oncoprotein network. Trends Biochem Sci. 2002;27(9):462–467. doi:10.1016/S0968-0004(02)02166-7
   PubMed Web of Science ®Google Scholar
• Wang Q, Cang Z, Shen L, et al. circ_0037128/miR-17-3p/AKT3 axis promotes the development of diabetic nephropathy. Gene. 2021;765:145076. doi:10.1016/j.gene.2020.145076
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288–1295. doi:10.1038/nm788
   PubMed Web of Science ®Google Scholar
• Wang W, Sun W, Cheng Y, Xu Z, Cai L. Role of sirtuin-1 in diabetic nephropathy. J Mol Med. 2019;97(3):291–309. doi:10.1007/s00109-019-01743-7
   PubMed Web of Science ®Google Scholar
• Papadimitriou A, Silva KC, Peixoto EBMI, Borges CM, Lopes de faria JM, Lopes de faria JB. Theobromine increases NAD +/Sirt-1 activity and protects the kidney under diabetic conditions. Am J Physiol Renal Physiol. 2014;308(3):F209–F225. doi:10.1152/ajprenal.00252.2014
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Wakino S, Simic P, et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med. 2013;19(11):1496–1504. doi:10.1038/nm.3363
   PubMed Web of Science ®Google Scholar
• Ruderman NB, Xu XJ, Nelson L, et al. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab. 2010;298(4):E751–E760. doi:10.1152/ajpendo.00745.2009
   PubMed Web of Science ®Google Scholar
• Xue W, Mao J, Chen Q, Ling W, Sun Y. Mogroside IIIE alleviates high glucose-induced inflammation, oxidative stress and apoptosis of podocytes by the activation of AMPK/SIRT1 signaling pathway. Diabetes Metabol Syndr Obes. 2020;13:3821–3830. doi:10.2147/DMSO.S276184
   PubMed Web of Science ®Google Scholar
• Chau MDL, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A. 2010;107(28):12553–12558. doi:10.1073/pnas.1006962107
   PubMed Web of Science ®Google Scholar
• Cai -Y-Y, Zhang H-B, Fan C-X, et al. Renoprotective effects of brown adipose tissue activation in diabetic mice. J Diabetes. 2019;11(12):958–970. doi:10.1111/1753-0407.12938
   PubMed Web of Science ®Google Scholar
• Papadimitriou A, Peixoto EBMI, Silva KC, Lopes de Faria JM, Lopes de Faria JB. Increase in AMPK brought about by cocoa is renoprotective in experimental diabetes mellitus by reducing NOX4/TGFβ-1 signaling. J Nutr Biochem. 2014;25(7):773–784. doi:10.1016/j.jnutbio.2014.03.010
   PubMed Web of Science ®Google Scholar
• Lin Q, Huang Z, Cai G, et al. Activating AMP-activated protein kinase mediates fibroblast growth factor 1 protection from nonalcoholic fatty liver disease in mice. Hepatology. 2020;73(6):2206.
   Web of Science ®Google Scholar
• Chen Q, Huang J, Gong W, et al. MRTF-A mediated FN and ICAM-1 expression in AGEs-induced rat glomerular mesangial cells via activating STAT5. Mol Cell Endocrinol. 2018;460:123–133. doi:10.1016/j.mce.2017.07.014
   PubMed Web of Science ®Google Scholar
• Yu J, Zhao L, Wang A, et al. Growth hormone stimulates transcription of the fibroblast growth factor 21 gene in the liver through the signal transducer and activator of transcription 5. Endocrinology. 2012;153(2):750–758. doi:10.1210/en.2011-1591
   PubMed Web of Science ®Google Scholar
• Huang J-S, Chuang L-Y, Guh J-Y, et al. Effect of nitric oxide-cGMP-dependent protein kinase activation on advanced glycation end-product–induced proliferation in renal fibroblasts. J Am Soc Nephrol. 2005;16(8):2318. doi:10.1681/ASN.2005010030
   PubMed Web of Science ®Google Scholar
• Zhou Y, Lv C, Wu C, Chen F, Shao Y, Wang Q. Suppressor of cytokine signaling (SOCS) 2 attenuates renal lesions in rats with diabetic nephropathy. Acta Histochem. 2014;116(5):981–988. doi:10.1016/j.acthis.2014.04.002
   PubMed Web of Science ®Google Scholar
• Kaltenecker D, Mueller KM, Benedikt P, et al. Adipocyte STAT5 deficiency promotes adiposity and impairs lipid mobilisation in mice. Diabetologia. 2017;60(2):296–305. doi:10.1007/s00125-016-4152-8
   PubMed Web of Science ®Google Scholar